Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted Group Therapy for Demoralization in AIDS Survivors
NCT02950467Phase 1Completed
- Start
- Jan 2018
- Primary completion
- Dec 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in demoralization syndrome. Primary endpoints: Number of Participants Who Experienced Treatment-related Adverse Events at 5 months and Subject Recruitment and Retention at 24 months. Started Jan 2018; status: completed.
02
Drugs
psilocybin
03
Conditions
demoralization syndrome
Beyond the preview
Go deeper on NCT02950467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02950467.